We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have been a shareholder in Tiziana for almost a year and have watched the share price rise and fall. I have asked myself on more than one occasion whether this is really likely to prove a worthwhile investment, but each time I do I take another look at the Tiziana website and see the life-changing difference Foralumab will potentially bring to so many people, and the track record of the medical team working on the programme I am convinced that sooner or later the company will be worth many multiples of what it is now. That view is reinforced by the fact that Gabrielle Cerrone has so much skin in the game, along with the smaller, though significant, investors, Fonda, Silverman and Freedberg who, having done some google research, surely know what they are doing.
The Accustem demerger/ flotation process has admittedly been much slower than anticipated, (I suspect that Covid may have contributed to the delay), but when the float finally happens, as I am confident it will, and there are any announcements about the phase 2 Brazil/ covid trial etc, TILS shares are likely to see a major bounce. My conclusion? Perseverance will pay...
Thank you.
So basically, the EC has the Lion's share.
That's good.
No major institutions though.
The Company's issued share capital comprises 194,612,289 ordinary shares of nominal value at 3p each.
The percentage of securities not in public hands is 39.52%.
Planwise Group LTD
63,297,647
32.52%*
Empery Asset Master, Ltd.
10,153,770
5.22%
Laura Fonda
7,971,966
4.10%
Morris Silverman
7,944,457
4.08%
Howard Freedberg
6,296,221
3.24%
*Gabriele Cerrone, Executive Chairman, is considered to have a beneficial interest in the shares and voting rights held Planwise Group Limited and Panetta Partners Limited, giving him an aggregate interest in share and voting rights equal to 34.070%
I was trying to find a list of the major investors here - I think because it was previous listed on the AIM market this sort of information is a little more opaque than it might otherwise be.
Does anyone here have a link to such a list>?